Business Operations:

Sector: Healthcare
Industry: Healthcare Plans

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

Revenue projections:

ELV's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio	1.518000
forwardPE	13.081779
debtToEquity	68.953000
earningsGrowth	-0.131000
revenueGrowth	0.014000
grossMargins	0.259900
operatingMargins	0.045590
trailingEps	22.590000
forwardEps	29.539560

With a current ratio of 1.518, ELV has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that ELV is in a strong position to meet its immediate financial obligations without difficulty.
ELV's Forward PE ratio is favorable, meaning the stock price aligns well with earnings and isn't overvalued. This allows room for growth, making it an attractive investment for those seeking potential upside while ensuring the stock is not overpriced.
ELV's low growth in both earnings and revenue indicates the company's profits may decrease. This trend could signal a downturn in financial performance, suggesting that ELV might struggle to maintain its current profit levels.
ELV's negative gross and operating margins point to financial difficulties, as the company is incurring losses at both the production and operational levels. This suggests a potential decline in profitability and raises concerns about its financial outlook.
ELV's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that ELV is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Elevance Health, Inc.'s stock price has regularly been near the lower end of projections, indicating that it may be struggling to attract investor interest. This pattern suggests a cautious sentiment surrounding the company's future performance.

Insider Transactions:

5 sales transactions of ELV were conducted, with market price at 356.2551025390625.There were 3 buy transactions of ELV, with market price at 323.2782796223958.More sells than buys at ELV's current price levels suggest a potential downside. If this selling trend persists, it could trigger further price declines, as increased selling often reflects investor pessimism about the stock's future prospects.

Recommendation changes over time:

Analysts' buy bias toward ELV suggests the stock is seen as a solid investment, potentially motivating investors to consider it for their portfolios. With this positive outlook, ELV is likely to be viewed as a secure place to allocate funds, driving further interest in the stock.